FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4280640178> ?p ?o ?g. }

• W4280640178 abstract "Abstract Background A recent survey revealed that extensive off-label use of sugammadex in pediatric anesthesia deserved particular attention. The present study with trial sequential analysis (TSA) aimed to evaluate the effects of sugammadex for antagonizing neuromuscular blockade (NMB) in pediatric patients, and to investigate whether the findings achieved the required information size to draw conclusions. Methods PubMed, Embase, Cochrane Library and China National Knowledge Infrastructure (CNKI) were searched from inception to April 2021. All randomized controlled trials used sugammadex as reversal agent in pediatric patients were enrolled. Time from NMB reversal to recovery of the train-of-four ratio (TOFr) to 0.9 and extubation time were considered as co-primary outcomes, and incidences of adverse events were considered as secondary outcomes. Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system was used to rate the quality of evidences. Results Data from 18 studies involving 1,065 pediatric patients were acquired. The results revealed that use of sugammadex was associated with shorter duration from administration of reversal agents to TOFr > 0.9 (MD = -14.42, with 95% CI [-17.08, -11.75]) and shorter interval from reversal from NMB to extubation (MD = -13.98, with 95% CI [-16.70, -11.26]) compared to control groups. TSA also indicated that the current sample sizes were sufficient with unnecessary further trials. Analysis of secondary outcomes indicated that administration of sugammadex was associated with less incidence of postoperative nausea and vomiting (PONV), bradycardia, and dry mouth compared to control groups. Conclusion Considering of satisfactory and rapid neuromuscular blockade reversal with low incidences of adverse events, sugammadex might be considered as the preferred option for children in clinical anesthesia practice compared to acetylcholinesterase inhibitors. However, overall low-quality evidences in present study rated by GRADE system indicated that superiority of sugammadex employed in pediatric patients needs to be confirmed by more studies with high quality and large sample size in future." @default.
• W4280640178 created "2022-05-22" @default.
• W4280640178 creator A5001877165 @default.
• W4280640178 creator A5004139292 @default.
• W4280640178 creator A5019858998 @default.
• W4280640178 creator A5027639672 @default.
• W4280640178 creator A5058253740 @default.
• W4280640178 creator A5060598531 @default.
• W4280640178 creator A5065112486 @default.
• W4280640178 creator A5073372533 @default.
• W4280640178 creator A5073968992 @default.
• W4280640178 date "2022-05-19" @default.
• W4280640178 modified "2023-10-09" @default.
• W4280640178 title "Efficacy and safety of sugammadex for neuromuscular blockade reversal in pediatric patients: an updated meta-analysis of randomized controlled trials with trial sequential analysis" @default.
• W4280640178 cites W1903034711 @default.
• W4280640178 cites W1968706118 @default.
• W4280640178 cites W1972328771 @default.
• W4280640178 cites W1989419447 @default.
• W4280640178 cites W2033585778 @default.
• W4280640178 cites W2044367689 @default.
• W4280640178 cites W2045332614 @default.
• W4280640178 cites W2064517847 @default.
• W4280640178 cites W2088351330 @default.
• W4280640178 cites W2116951140 @default.
• W4280640178 cites W2121053349 @default.
• W4280640178 cites W2136403658 @default.
• W4280640178 cites W2148906704 @default.
• W4280640178 cites W2149441166 @default.
• W4280640178 cites W2153801682 @default.
• W4280640178 cites W2156098321 @default.
• W4280640178 cites W2157263718 @default.
• W4280640178 cites W2168157935 @default.
• W4280640178 cites W2171132967 @default.
• W4280640178 cites W2322734886 @default.
• W4280640178 cites W2328203160 @default.
• W4280640178 cites W2512875740 @default.
• W4280640178 cites W2514921657 @default.
• W4280640178 cites W2550560683 @default.
• W4280640178 cites W2567362164 @default.
• W4280640178 cites W2586436858 @default.
• W4280640178 cites W2614315895 @default.
• W4280640178 cites W2734760165 @default.
• W4280640178 cites W2744085373 @default.
• W4280640178 cites W2749176690 @default.
• W4280640178 cites W2944289068 @default.
• W4280640178 cites W2965884268 @default.
• W4280640178 cites W2971822478 @default.
• W4280640178 cites W2978795816 @default.
• W4280640178 cites W2991792334 @default.
• W4280640178 cites W3006600543 @default.
• W4280640178 cites W3009228367 @default.
• W4280640178 cites W3019758936 @default.
• W4280640178 cites W3039088017 @default.
• W4280640178 cites W3083588777 @default.
• W4280640178 cites W3127534757 @default.
• W4280640178 doi "https://doi.org/10.1186/s12887-022-03288-0" @default.
• W4280640178 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35590273" @default.
• W4280640178 hasPublicationYear "2022" @default.
• W4280640178 type Work @default.
• W4280640178 citedByCount "3" @default.
• W4280640178 countsByYear W42806401782022 @default.
• W4280640178 countsByYear W42806401782023 @default.
• W4280640178 crossrefType "journal-article" @default.
• W4280640178 hasAuthorship W4280640178A5001877165 @default.
• W4280640178 hasAuthorship W4280640178A5004139292 @default.
• W4280640178 hasAuthorship W4280640178A5019858998 @default.
• W4280640178 hasAuthorship W4280640178A5027639672 @default.
• W4280640178 hasAuthorship W4280640178A5058253740 @default.
• W4280640178 hasAuthorship W4280640178A5060598531 @default.
• W4280640178 hasAuthorship W4280640178A5065112486 @default.
• W4280640178 hasAuthorship W4280640178A5073372533 @default.
• W4280640178 hasAuthorship W4280640178A5073968992 @default.
• W4280640178 hasBestOaLocation W42806401781 @default.
• W4280640178 hasConcept C126322002 @default.
• W4280640178 hasConcept C141071460 @default.
• W4280640178 hasConcept C168563851 @default.
• W4280640178 hasConcept C197934379 @default.
• W4280640178 hasConcept C2776478404 @default.
• W4280640178 hasConcept C2776988050 @default.
• W4280640178 hasConcept C2777297131 @default.
• W4280640178 hasConcept C2778560516 @default.
• W4280640178 hasConcept C2778716859 @default.
• W4280640178 hasConcept C2780580376 @default.
• W4280640178 hasConcept C2909465803 @default.
• W4280640178 hasConcept C42219234 @default.
• W4280640178 hasConcept C71924100 @default.
• W4280640178 hasConcept C95190672 @default.
• W4280640178 hasConceptScore W4280640178C126322002 @default.
• W4280640178 hasConceptScore W4280640178C141071460 @default.
• W4280640178 hasConceptScore W4280640178C168563851 @default.
• W4280640178 hasConceptScore W4280640178C197934379 @default.
• W4280640178 hasConceptScore W4280640178C2776478404 @default.
• W4280640178 hasConceptScore W4280640178C2776988050 @default.
• W4280640178 hasConceptScore W4280640178C2777297131 @default.
• W4280640178 hasConceptScore W4280640178C2778560516 @default.
• W4280640178 hasConceptScore W4280640178C2778716859 @default.
• W4280640178 hasConceptScore W4280640178C2780580376 @default.
• W4280640178 hasConceptScore W4280640178C2909465803 @default.
• W4280640178 hasConceptScore W4280640178C42219234 @default.
• W4280640178 hasConceptScore W4280640178C71924100 @default.

• next